Drug Trial Radar · NCT02741258
Mepitel Film Treatment for the Prevention and Cutaneous Toxicity Due to Radiotherapy
Last checked: Nov 19, 2026Latest source record: Jul 5, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
164
Actual
Start
Oct 1, 2015
Primary completion
Dec 31, 2021
Study completion Dec 31, 2021
Sponsor
- Lead sponsor
- Dario ValcarenghiAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 18, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized study, mepitel vs standard of care for the prevention and skin toxicity due to radiotherapy in patients with post-surgery breast cancer. Mepitel film will be placed on the skin of the patients just before the start of the radiotherapy and will be replaced once a week until the end of the radiotherapy. In case of skin toxicities mepitel film will be placed until resolution of toxicities.
Conditions
- Post-surgery Radiotherapy
Interventions
Mepitel FilmDevice
Placement of Mepitel Film to prevent skin toxicity
skin creamDrug
cream to treat skin erythema due to radiotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mepitel Film efficacy in treating skin toxicity evaluatet with Common Terminology Criteria for Adverse Events (CTCAE)Time frame: one week after start of radiotherapy
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Oncology Institute of Southern Switzerland
Bellinzona, Switzerland
Institut für Radiotherapie Klinik Hirslanden
Zurich, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.